Vir Biotechnology recently announced it will present data from its Phase 2 SOLSTICE trial of the tobevibart-elebsiran combination for chronic hepatitis delta at the EASL Congress 2026 in Barcelona, ...
Chronic hepatitis delta virus (HDV) infection has its first FDA-approved treatment, after the agency granted accelerated approval to bulevirtide (Hepcludex) injection for adults without cirrhosis or ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted marketing authorization for Cepheid’s Xpert HCV test and GeneXpert Xpress System, the first ...
Why does Hepatitis E become chronic in some patients, and why do medications not work? To find out, an international research team led by scientists from Bochum observed a patient with chronic ...
Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen (HBsAg). Their efficacy and safety in the treatment of chronic hepatitis D ...
A CRISPR-based antiviral strategy suppressed hepatitis E virus replication in cell cultures. Researchers used targeted ...
Food And Drug Administration approves first-ever treatment for hepatitis delta, offering hope to 80,000 Americans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results